Overview
Stay up to date with the latest developments in therapeutics by reading the world’s most respected source of authoritative drug information. For 50 years Drugs has been the definitive journal of drugs and therapeutics, promoting optimum pharmacotherapy by publishing reviews and original research authored by leading international clinicians and researchers to support clinical decision-making.
Through a rigorous and comprehensive program of peer-reviewed evaluations, Drugs provides detailed and objective analysis covering the full spectrum of new and established drug therapies in all disease areas.
As a hybrid journal, Drugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require (more information).
Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content (more information).
- Editor
-
- Dene Peters
- Impact factor
- 11.5 (2022)
- 5 year impact factor
- 10.5 (2022)
- Submission to first decision (median)
- 7 days
- Downloads
- 1,443,348 (2023)
Latest articles
Journal updates
-
-
Digital Features
Drugs is able to host a range of digital features, with a number of options available to authors.
Journal information
- Electronic ISSN
- 1179-1950
- Print ISSN
- 0012-6667
- Abstracted and indexed in
-
- BFI List
- BIOSIS
- Baidu
- CAB Abstracts
- CLOCKSS
- CNKI
- CNPIEC
- Chemical Abstracts Service (CAS)
- Current Contents/Clinical Medicine
- Current Contents/Life Sciences
- Dimensions
- EBSCO
- EMBASE
- EMBiology
- EMCare
- Google Scholar
- Japanese Science and Technology Agency (JST)
- Medline
- Naver
- OCLC WorldCat Discovery Service
- Pathway Studio
- Portico
- ProQuest
- Reaxys
- SCImago
- SCOPUS
- Science Citation Index Expanded (SCIE)
- Semantic Scholar
- TD Net Discovery Service
- UGC-CARE List (India)
- Wanfang
- Copyright information